Styrax Capital’s Guardant Health GH Stock Holding History

Styrax Capital’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,000	Closed	-$27.7M	–	20
2026 Q1	$27.7M	Buy	300,000 +18,411	+7%	+$1.85M	1.94%	16
2025 Q4	$28.8M	Buy	+281,589	New	+$25.2M	2.2%	15

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Styrax Capital's GH Position: Q2 2026 in Review

Styrax Capital sold out of Guardant Health (GH) in Q2 2026, closing a stake of 300,000 shares — an estimated $27.7M sold.

Styrax Capital first reported a position in GH in Q4 2025 and held it in 2 quarters. The position peaked at $28.8M in Q4 2025. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Styrax Capital reported no remaining Guardant Health position as of Q2 2026 after selling out during the quarter.
Styrax Capital sold 300,000 Guardant Health shares in Q2 2026, an estimated $27.7M.
Styrax Capital first reported a position in Guardant Health in Q4 2025 and held it in 2 quarters.
Styrax Capital's Guardant Health position peaked at $28.8M in Q4 2025.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Styrax Capital's 13F filing for Q2 2026, filed 14 Aug 2026.